Zur Seitennavigation oder mit Tastenkombination für den
accesskey
-Taste und Taste 1
Zum Seiteninhalt oder mit Tastenkombination für den
accesskey
und Taste 2
S
tartseite
A
nmelden
Sommer 2024
Hilfe
Sitemap
Impressum
Datenschutz
node2
Studentisches Leben
Veranstaltungen
Einrichtungen
Räume und Gebäude
Personen
Forschung
Startseite
Publikation: Zeitschriftenartikel
Neglected geriatric assessment and overtreatment of older patients with pancreatic cancer
Grunddaten
Abstract
Autoren
Einrichtung
Grunddaten
Titel
Neglected geriatric assessment and overtreatment of older patients with pancreatic cancer
Untertitel
results from a prospective phase IV clinical trial
Erscheinungsjahr
2022
Seiten (von – bis)
662 – 666
Band
13
Heft-Nr.
5
Jahr
2022
Publikationsform
Elektronische Ressource
Publikationsart
Zeitschriftenartikel
Sprache
Englisch
DOI
10.1016/j.jgo.2021.12.018
Letzte Änderung
14.07.2022 06:01:59
Bearbeitungsstatus
durch UB Rostock abschließend validiert
Dauerhafte URL
http://purl.uni-rostock.de/fodb/pub/68270
Links zu Katalogen
Abstract
Background - Older patients with metastatic pancreatic cancer may suffer increased toxicity from intensive chemotherapy. Treatment individualization by geriatric assessment (GA) might improve functional outcome. - Methods - We performed a multicenter, phase IV, open label trial in patients 70 years with metastatic pancreatic adenocarcinoma. Patients underwent GA and were assigned to one of three categories based on their scores: Go-Go, Slow-Go, or Frail. These categories were intended to guide physician's treatment decisions when choosing to treat patients with nab-paclitaxel/gemcitabine (arm A), gemcitabine (arm B), or best supportive care (arm C). Primary objective was a stable (loss of five points or less) Barthel's Activities of Daily Living (ADL) score during chemotherapy; secondary endpoints included GA scores during therapy, safety, quality of life, response and survival rates. - Results - Thirty-two patients were enrolled in the trial in six centers in Germany (out of 135 planned), resulting in termination due to low recruitment. Fifteen patients were allocated to nab-paclitaxel/gemcitabine, fifteen to gemcitabine, and two to best supportive care by their physicians, although according to their GA scores 29 patients (91%) were categorized as Slow-Go and three (9%) as Go-Go. Thus, fifteen of 32 (47%) patients were misclassified and given a course of treatment inconsistent with their GA scores. Median progression-free survival (PFS) were 3.3 months and 9.1 months and median time to quality-of-life deterioration 13 days and 29 days in the nab-paclitaxel/gemcitabine and gemcitabine monotherapy arms, respectively. Serious adverse events were reported in 11 (78.6%) patients in the nab-paclitaxel/gemcitabine and 8 (53.3%) patients in the gemcitabine arm. - Conclusions - Clinical evaluations by investigators differed markedly from geriatric assessments, leading to potential overtreatment. In our modest sample size study, those patients undergoing more intensive therapy had a less favorable course.
Autoren
Betge, Johannes
Schulte, Nadine
Belle, Sebastian
Zhan, Tianzuo
Krammer-Steiner, Beate
Moulin, Jean-Charles
Kleiß, Matthias
Lammert, Frank
Wedding, Ulrich
Räth, Sebastian
Maenz, Martin
Hegele, Lisa
Larcher-Senn, Julian
Jesenofsky, Ralf
Ebert, Matthias
Härtel, Nicolai
Einrichtung
UMR/ZIM/Klinik und Poliklinik für Innere Medizin III